Selected research
Industry Research
SARS-CoV-2 IgG (RBD) ELISA Industry Research Report 2026
Market perspective
The global SARS-CoV-2 IgG (RBD) ELISA market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the SARS-CoV-2 IgG (RBD) ELISA market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the SARS-CoV-2 IgG (RBD) ELISA market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the SARS-CoV-2 IgG (RBD) ELISA market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of SARS-CoV-2 IgG (RBD) ELISA include ALPCO, BD Biosciences, BioMérieux, Bio-Rad Laboratories, Enzo Life Sciences, LG, LOEWE Biochemica, Ortho Clinical Diagnostics and R&D Systems, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global SARS-CoV-2 IgG (RBD) ELISA market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to SARS-CoV-2 IgG (RBD) ELISA.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
SARS-CoV-2 IgG (RBD) ELISA Market by Company
ALPCO
BD Biosciences
BioMérieux
Bio-Rad Laboratories
Enzo Life Sciences
LG
LOEWE Biochemica
Ortho Clinical Diagnostics
R&D Systems
Shenzhen YHLO Biotech
ZEUS Scientific
Thermo Fisher Scientific
SARS-CoV-2 IgG (RBD) ELISA Segment by Type
ELISA Sets
ELISA Kits
SARS-CoV-2 IgG (RBD) ELISA Segment by Application
Hospital
Clinic
Disease control and prevention system
SARS-CoV-2 IgG (RBD) ELISA Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global SARS-CoV-2 IgG (RBD) ELISA market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of SARS-CoV-2 IgG (RBD) ELISA and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of SARS-CoV-2 IgG (RBD) ELISA.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of SARS-CoV-2 IgG (RBD) ELISA companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- ELISA Sets
- ELISA Kits
Applications
- Hospital
- Clinic
- Disease control and prevention system
Companies covered
- ALPCO
- BD Biosciences
- BioMérieux
- Bio-Rad Laboratories
- Enzo Life Sciences
- LG
- LOEWE Biochemica
- Ortho Clinical Diagnostics
- R&D Systems
- Shenzhen YHLO Biotech
- ZEUS Scientific
- Thermo Fisher Scientific
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 SARS-CoV-2 IgG (RBD) ELISA by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 ELISA Sets
- 2.2.3 ELISA Kits
- 2.3 SARS-CoV-2 IgG (RBD) ELISA by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Clinic
- 2.3.4 Disease control and prevention system
- 2.4 Assumptions and Limitations
3 SARS-CoV-2 IgG (RBD) ELISA Breakdown Data by Type
- 3.1 Global SARS-CoV-2 IgG (RBD) ELISA Historic Market Size by Type (2021-2026)
- 3.2 Global SARS-CoV-2 IgG (RBD) ELISA Forecasted Market Size by Type (2027-2032)
4 SARS-CoV-2 IgG (RBD) ELISA Breakdown Data by Application
- 4.1 Global SARS-CoV-2 IgG (RBD) ELISA Historic Market Size by Application (2021-2026)
- 4.2 Global SARS-CoV-2 IgG (RBD) ELISA Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global SARS-CoV-2 IgG (RBD) ELISA Market Perspective (2021-2032)
- 5.2 Global SARS-CoV-2 IgG (RBD) ELISA Growth Trends by Region
- 5.2.1 Global SARS-CoV-2 IgG (RBD) ELISA Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 SARS-CoV-2 IgG (RBD) ELISA Historic Market Size by Region (2021-2026)
- 5.2.3 SARS-CoV-2 IgG (RBD) ELISA Forecasted Market Size by Region (2027-2032)
- 5.3 SARS-CoV-2 IgG (RBD) ELISA Market Dynamics
- 5.3.1 SARS-CoV-2 IgG (RBD) ELISA Industry Trends
- 5.3.2 SARS-CoV-2 IgG (RBD) ELISA Market Drivers
- 5.3.3 SARS-CoV-2 IgG (RBD) ELISA Market Challenges
- 5.3.4 SARS-CoV-2 IgG (RBD) ELISA Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top SARS-CoV-2 IgG (RBD) ELISA Players by Revenue
- 6.1.1 Global Top SARS-CoV-2 IgG (RBD) ELISA Players by Revenue (2021-2026)
- 6.1.2 Global SARS-CoV-2 IgG (RBD) ELISA Revenue Market Share by Players (2021-2026)
- 6.2 Global SARS-CoV-2 IgG (RBD) ELISA Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of SARS-CoV-2 IgG (RBD) ELISA Head Office and Area Served
- 6.4 Global SARS-CoV-2 IgG (RBD) ELISA Players, Product Type & Application
- 6.5 Global SARS-CoV-2 IgG (RBD) ELISA Manufacturers Established Date
- 6.6 Global SARS-CoV-2 IgG (RBD) ELISA Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America SARS-CoV-2 IgG (RBD) ELISA Market Size (2021-2032)
- 7.2 North America SARS-CoV-2 IgG (RBD) ELISA Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America SARS-CoV-2 IgG (RBD) ELISA Market Size by Country (2021-2026)
- 7.4 North America SARS-CoV-2 IgG (RBD) ELISA Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe SARS-CoV-2 IgG (RBD) ELISA Market Size (2021-2032)
- 8.2 Europe SARS-CoV-2 IgG (RBD) ELISA Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe SARS-CoV-2 IgG (RBD) ELISA Market Size by Country (2021-2026)
- 8.4 Europe SARS-CoV-2 IgG (RBD) ELISA Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific SARS-CoV-2 IgG (RBD) ELISA Market Size (2021-2032)
- 9.2 Asia-Pacific SARS-CoV-2 IgG (RBD) ELISA Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific SARS-CoV-2 IgG (RBD) ELISA Market Size by Country (2021-2026)
- 9.4 Asia-Pacific SARS-CoV-2 IgG (RBD) ELISA Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America SARS-CoV-2 IgG (RBD) ELISA Market Size (2021-2032)
- 10.2 South America SARS-CoV-2 IgG (RBD) ELISA Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America SARS-CoV-2 IgG (RBD) ELISA Market Size by Country (2021-2026)
- 10.4 South America SARS-CoV-2 IgG (RBD) ELISA Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa SARS-CoV-2 IgG (RBD) ELISA Market Size (2021-2032)
- 11.2 Middle East & Africa SARS-CoV-2 IgG (RBD) ELISA Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa SARS-CoV-2 IgG (RBD) ELISA Market Size by Country (2021-2026)
- 11.4 Middle East & Africa SARS-CoV-2 IgG (RBD) ELISA Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 ALPCO
- 12.1.1 ALPCO Company Information
- 12.1.2 ALPCO Business Overview
- 12.1.3 ALPCO Revenue in SARS-CoV-2 IgG (RBD) ELISA Business (2021-2026)
- 12.1.4 ALPCO SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
- 12.1.5 ALPCO Recent Developments
- 12.2 BD Biosciences
- 12.2.1 BD Biosciences Company Information
- 12.2.2 BD Biosciences Business Overview
- 12.2.3 BD Biosciences Revenue in SARS-CoV-2 IgG (RBD) ELISA Business (2021-2026)
- 12.2.4 BD Biosciences SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
- 12.2.5 BD Biosciences Recent Developments
- 12.3 BioMérieux
- 12.3.1 BioMérieux Company Information
- 12.3.2 BioMérieux Business Overview
- 12.3.3 BioMérieux Revenue in SARS-CoV-2 IgG (RBD) ELISA Business (2021-2026)
- 12.3.4 BioMérieux SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
- 12.3.5 BioMérieux Recent Developments
- 12.4 Bio-Rad Laboratories
- 12.4.1 Bio-Rad Laboratories Company Information
- 12.4.2 Bio-Rad Laboratories Business Overview
- 12.4.3 Bio-Rad Laboratories Revenue in SARS-CoV-2 IgG (RBD) ELISA Business (2021-2026)
- 12.4.4 Bio-Rad Laboratories SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
- 12.4.5 Bio-Rad Laboratories Recent Developments
- 12.5 Enzo Life Sciences
- 12.5.1 Enzo Life Sciences Company Information
- 12.5.2 Enzo Life Sciences Business Overview
- 12.5.3 Enzo Life Sciences Revenue in SARS-CoV-2 IgG (RBD) ELISA Business (2021-2026)
- 12.5.4 Enzo Life Sciences SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
- 12.5.5 Enzo Life Sciences Recent Developments
- 12.6 LG
- 12.6.1 LG Company Information
- 12.6.2 LG Business Overview
- 12.6.3 LG Revenue in SARS-CoV-2 IgG (RBD) ELISA Business (2021-2026)
- 12.6.4 LG SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
- 12.6.5 LG Recent Developments
- 12.7 LOEWE Biochemica
- 12.7.1 LOEWE Biochemica Company Information
- 12.7.2 LOEWE Biochemica Business Overview
- 12.7.3 LOEWE Biochemica Revenue in SARS-CoV-2 IgG (RBD) ELISA Business (2021-2026)
- 12.7.4 LOEWE Biochemica SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
- 12.7.5 LOEWE Biochemica Recent Developments
- 12.8 Ortho Clinical Diagnostics
- 12.8.1 Ortho Clinical Diagnostics Company Information
- 12.8.2 Ortho Clinical Diagnostics Business Overview
- 12.8.3 Ortho Clinical Diagnostics Revenue in SARS-CoV-2 IgG (RBD) ELISA Business (2021-2026)
- 12.8.4 Ortho Clinical Diagnostics SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
- 12.8.5 Ortho Clinical Diagnostics Recent Developments
- 12.9 R&D Systems
- 12.9.1 R&D Systems Company Information
- 12.9.2 R&D Systems Business Overview
- 12.9.3 R&D Systems Revenue in SARS-CoV-2 IgG (RBD) ELISA Business (2021-2026)
- 12.9.4 R&D Systems SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
- 12.9.5 R&D Systems Recent Developments
- 12.10 Shenzhen YHLO Biotech
- 12.10.1 Shenzhen YHLO Biotech Company Information
- 12.10.2 Shenzhen YHLO Biotech Business Overview
- 12.10.3 Shenzhen YHLO Biotech Revenue in SARS-CoV-2 IgG (RBD) ELISA Business (2021-2026)
- 12.10.4 Shenzhen YHLO Biotech SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
- 12.10.5 Shenzhen YHLO Biotech Recent Developments
- 12.11 ZEUS Scientific
- 12.11.1 ZEUS Scientific Company Information
- 12.11.2 ZEUS Scientific Business Overview
- 12.11.3 ZEUS Scientific Revenue in SARS-CoV-2 IgG (RBD) ELISA Business (2021-2026)
- 12.11.4 ZEUS Scientific SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
- 12.11.5 ZEUS Scientific Recent Developments
- 12.12 Thermo Fisher Scientific
- 12.12.1 Thermo Fisher Scientific Company Information
- 12.12.2 Thermo Fisher Scientific Business Overview
- 12.12.3 Thermo Fisher Scientific Revenue in SARS-CoV-2 IgG (RBD) ELISA Business (2021-2026)
- 12.12.4 Thermo Fisher Scientific SARS-CoV-2 IgG (RBD) ELISA Product Portfolio
- 12.12.5 Thermo Fisher Scientific Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst